215453-35-3

Usage

Uses

Used in Pharmaceutical Industry:
Thieno[3,2-c]pyridin-4-amine (9CI) is used as a key intermediate in the synthesis of various drugs and compounds. Its unique structure and functional groups make it a valuable building block for the development of new molecules with potential therapeutic applications.
Used in Medicinal Chemistry Research:
Thieno[3,2-c]pyridin-4-amine (9CI) is employed as a research compound in medicinal chemistry. Its diverse biological activities and potential as a therapeutic agent make it an attractive candidate for the discovery and development of novel pharmaceuticals.

InChI:InChI=1/C7H6N2S/c8-7-5-2-4-10-6(5)1-3-9-7/h1-4H,(H2,8,9)

Upstream product

• 27685-92-3 thieno[3,2-c]pyridin-4-ol 
• 27685-94-5 4-chlorothieno[3,2-c]pyridine 

Downstream Products

• 215453-36-4 N-(thieno[3,2-c]pyridin-4-yl)benzamide 
• 215453-39-7 2-(4-benzoylamino-thieno[3,2-c]pyridin-2-ylmethyl)-2-tert-butoxycarbonylamino-malonic acid diethyl ester 
• 215453-38-6 N-(2-hydroxymethyl-thieno[3,2-c]pyridin-4-yl)-benzamide 

Relevant academic research and scientific papers

ENZYME INHIBITORS

The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.

ENZYME INHIBITORS

The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.

ENZYME INHIBITORS

The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors

Replacement of the highly basic benzamidine moiety with moderate basic amino-bicycloaryl moieties in a series of thrombin inhibitors related to NAPAMP provided potent enzyme inhibition and significant improvements in membrane transport and oral bioavailability.